Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Abbott India: Modest growth - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 3, 2003

    Abbott India: Modest growth

    MNC pharma major, Abbott India has recently announced its 3QFY04 results. While the company registered a modest 7% increase in topline, bottomline shot up by a significant 60%. For 9mFY04, Abbot registered a 5% growth in net sales and 29% rise in net profits. In this context, let us briefly evaluate the company’s performance.

    Steady growth…
    (Rs m) 3QFY03 3QFY04 Change 9mFY03 9mFY04 Change
    Net Sales 969 1,041 7.4% 2,632 2,754 4.6%
    Other Income 20 23 12.2% 117 152 29.0%
    Total expenditure 749 780 4.2% 2,065 2,144 3.8%
    Operating Profit (EBDIT) 220 261 18.4% 567 610 7.5%
    Operating Profit Margin (%) 22.7% 25.1%   21.6% 22.2%  
    Interest 0 0 20.0% 1 0 -78.5%
    Depreciation 15 11 -31.2% 42 31 -25.0%
    Profit before Tax 225 273 21.2% 642 730 13.7%
    Extra-ordinary items (31) 0 -100.0% -31 0 -100.0%
    Tax 72 77 6.7% 198 199 0.2%
    Profit after Tax/(Loss) 123 196 60.3% 413 531 28.7%
    Net profit margin (%) 12.6% 18.9%   15.7% 19.3%  
    No. of Shares (m) 16.2 15.3   16.2 15.3  
    Earnings per share* 30.2 51.4   34.0 46.4  
    P/E ratio   6.6     7.3  

    During 3QFY04, the domestic pharma industry has seen a revival in demand. However, the industry has still not witnessed its traditional double-digit growth rates. In line with the industry performance, Abbott India has managed to register a modest growth its topline. The growth was fuelled by the company’s strong anti-diabetics portfolio. On the operations front, a drop in the raw material cost and other expenditure by 2 percentage points and 1 percentage point respectively has helped Abbott India improve its operating margins. This coupled with a drop in the depreciation provisioning has resulted in the company recording a sharp 60% growth in the bottomline. However, it is to be noted here that in 3QFY03 last year, the company had reported for extra-ordinary loss of Rs 31 m on the sale of its Jejuri undertaking. If the same is excluded, the net profit growth drops to 28% YoY.

    For 9mFY04, Abbott India’s performance was affected by the slowdown in the domestic market and the VAT fiasco. Infact, the company recorded stagnant/negative growth in most therapeutic segments other than the anti-diabetics segment. Resultantly, the topline grew by 5% and the bottomline by 29%. However, here again, if the losses booked during 9mFY03 in relation to the sale of the Jejuri undertaking are ignored, the net profit growth becomes 20%.

    As was mentioned earlier, Abbott India has a strong presence in the anti-diabetics segment with animal insulins being its major product. Recently, Wockhardt had launched recombinant human insulins at low prices. This could affect Abbott India’s performance going forward as human insulins might be preferred to animal insulins by users who were earlier averse to the switchover on account of the high prices of human insulins. Another major concerning factor is Abbott India’s large exposure to DPCO. This has affected the company’s ability to fix prices and consequently stunted its topline growth. Recently, National Pharmaceuticals Pricing Authority (NPPA) ruling resulted in reduction of 3 Abbot products. This is likely to affect the performance of the company in the near term.

    NPPA effect…
    Formulation/Composition Name Pack Size Existing Price (Rs.) Revised Price (Rs.) Change (%)
    Erykid-125 DIS Tablet 10's Blister 18.0 15.1 (16.3)
    Erythromycin Ethyl Succinate Tablet 6's Al_St 45.3 35.8 (21.1)
    Erythromycin Ethyl Succinate Tablet 6's Al_Bl 45.0 35.5 (21.2)

    At Rs 338, Abbott India is trading at a P/E of 7x its 9mFY04 earnings. A high DPCO cover and competition led drop in human insulins prices could affect the performance of the company in the near term. Further, absence of product patents and a consequent reluctance by the parent in launching new products has affected company’s growth in the past. However, with product patents being introduced post 2005, things could improve. With the domestic pharma market now showing signs of recovery, we remain optimistic about the prospects of the company given the fact that it recorded a 6% growth in revenues in August ’03.



    Equitymaster requests your view! Post a comment on "Abbott India: Modest growth". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts